Phaseline

Targets › GP160

GP160: drug programs, companies and trials

2 programs from 1 company in 3 trials: 3 Phase 1; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on GP160, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Institute of Allergy and Infectious Diseases (NIAID)CH505 TF mRNA-gp160
mRNA-gp160 encapsulated in lipid nanoparticles (LNPs) expressing HIV envelope protein to b
GP160Phase 1HIV Infections; HIVMar 2027
National Institute of Allergy and Infectious Diseases (NIAID)CH505M5 N197D mRNA-gp160
mRNA-gp160 encapsulated in lipid nanoparticles (LNPs) expressing HIV envelope protein to i
GP160Phase 1HIV InfectionsMar 2027

Conditions

HIV Infections (2) HIV (1)

Modalities

other (2)

Companies

National Institute of Allergy and Infectious Diseases (NIAID) (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.